GENUS

Genus reported an adjusted pre-tax profit of £100.2m and adjusted EPS of 110.3p for H2 2026—both up 35%—with free cash flow of £62m. Reported revenue fell 2% to £658.1m, mainly due to the deconsolidation of PIC China. The company expects moderate profit growth in 2027, weighted to the second half, and announced a 10% dividend increase to 35.2p plus a £60m share buyback programme. Despite improved profitability, the stock fell 6.65% pre-market as investors weighed the revenue decline, the H2‑weighted outlook and regional headwinds more heavily. » Más en de.investing.com

Genus shares fell 6.5% after preliminary results for 2026 showed adjusted revenue down 2% to £658.1m, missing consensus. The decline in revenue was mainly due to the deconsolidation of PIC China following the formation of a joint venture with Beijing Capital Agribusiness. Positive: adjusted operating profit rose 25% to £116.0m and adjusted pre-tax profit rose 35% to £100.2m, supported by strong PIC growth and a £5.6m milestone payment. Genus announced a £60m share buyback programme but warned adjusted pre-tax earnings for 2027 are likely to be weighted heavily to the second half due to disease-related issues in North American pig production and lower hog and milk prices. » Más en de.investing.com

Genus forecasts an adjusted pre-tax profit of around £98m for fiscal 2026, beating consensus estimates. The positive revision reflects a stronger-than-expected second half, with robust growth in the pig genetics business (PIC) in Asia and Latin America and double-digit profit growth at the cattle genetics division (ABS) thanks to the Value Acceleration Programme. The company also reports very strong cash conversion, material free cash flow growth and a strengthened balance sheet heading into FY27. The shares rose sharply intraday and closed well above the prior level. » Más en de.investing.com

Genus reports adjusted profit growth of 57% for H1 2026 on flat revenue of £335.6m; adjusted pre-tax profit rose to £55.7m and adjusted earnings per share to 60.8p. Drivers were high-margin licence revenues, strong PIC performance in Asia and a £5.6m milestone payment from a joint venture with Beijing Capital Agribusiness, which expects further payments of around £100m for Q4 FY2026. Regulatory progress for the PRRS‑resistant PRP technology and an increase of the interim dividend to 11.2p underline the strategy, while the shares fell sharply amid doubts about the sustainability of the margins. » Más en de.investing.com

Genus reported a strong first half of 2026 with an adjusted pre-tax profit of around £50.0m (excluding a milestone payment) or about £55.6m including the milestone. Management now expects a full-year adjusted pre-tax profit to be moderately above the top end of current market expectations (£82.7–85.0m). In December Genus received SASAC approval for the China pig genetics joint venture, triggering a $7.5m (approximately £5.6m) milestone payment; formation and payment are expected in Q3. The full half-year results for the period to 31 December 2025 will be published on 26 February 2026. » Más en de.investing.com